Anocca develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies using a proprietary discovery engine and programmable human cells. Its lead programme, VIDAR-1, is the first non-viral gene-edited TCR-T cell therapy in Europe and targets mutant KRAS in pancreatic ductal adenocarcinoma. The company operates an in-house cGMP manufacturing and process development facility in Södertälje, Sweden and runs a custom software ecosystem called AnoccaOS. Anocca says it has the broadest pipeline of TCR-T oncology cell therapy treatments and a team of 130+ staff from 40+ nations. The company plans to use new financing to drive VIDAR-1 through early-stage clinical development and to advance its preclinical pipeline. Phase I recruitment for VIDAR-1 is open at university hospitals across Sweden, Denmark, Germany and the Netherlands. Anocca AB develops cancer cell therapies using proprietary analytical methods to identify and produce tumour-specific T-cells and matching T-cell receptors (TCRs). The company has automated its research platform and aims to manufacture TCR-T therapies on an industrial scale. Operations and manufacturing are located at former AstraZeneca facilities in Södertälje, Sweden. Anocca plans to use the new capital to expand research, development, and manufacturing capabilities and to progress its first products into clinical trials, with a first clinical trial planned to be initiated in 2024. Founded in 2014 and led by CEO Reagan Jarvis, the company employs about 100 people. Including the current raise, Anocca has received SEK 1.3 billion in venture capital and in December 2022 secured a EUR 25M venture debt facility from the European Investment Bank. Anocca engineers next-generation T-cell immunotherapies and is building libraries of novel T-cell therapies targeting difficult-to-treat solid tumours. The company intends to move its T-cell immunotherapies into clinical trials in a solid-tumour indication and aims to enter clinical trials in 2024. Alongside its oncology programs, Anocca's proprietary technologies are being applied to the development of vaccines and treatments for autoimmune diseases. Led by CEO Reagan Jarvis and founded in 2014, the company is based in Södertälje, Sweden. Financially, Anocca has previously raised €100 million from leading Nordic investors and recently secured additional financing to advance its pipeline. The new funds are intended to support progression of its programs toward clinical development. Anocca develops TCR‑modified T‑cell (TCR‑T) therapies using a proprietary, industrialised analytical cell biology platform that replicates human T‑cell biology in the laboratory. Its platform combines proprietary cell biology and molecular genetics technologies with integrated information management and bioinformatic software tools to enable scalable, high‑precision analysis. The company has generated a broad pipeline of TCR‑T assets targeting multiple antigen classes, including shared tumour targets, cancer-driving mutations and oncogenic viruses. Anocca operates an in‑house cGMP clinical manufacturing and process development facility and emphasises automation and software to drive multiple clinical programmes in parallel. The company plans to use the financing to accelerate its oncology pipeline into Phase I/IIa clinical trials and to bolster its in‑house manufacturing capabilities. Anocca was founded in 2014 and employs over 65 people at its Södertälje, Sweden site.

Total raised

$155M

Funding rounds

4

Latest round

Equity

Latest activity

Aug 2025